French Pharmaceutical Companies Association

An important feature of the code is its universal applicability. All companies that are members of an affiliated trade association (e.g. ABPI [Association of British Pharmaceutical Industries], LEEM [Les enterprises du medicament or French Pharmaceutical Companies Association], LIF [Swedish Association of the Pharmaceutical Industry], Interpharma) are required to apply the minimum standards of the code wherever they do business. Companies entering into licensing and agency agreements are expected to require their licensees and agents to respect the provisions of the IFPMA code. 

Vinorelbine demonstrated important antitumour properties associated with reduced toxic side effects and its application was developed during the 1980 s by the French pharmaceutical company Pierre Fabre Medicaments, under the commercial name Navelbine . Vinorelbine is now widely used in the treatment of non-small cell lung cancer and breast cancer, and several other potential indications are under clinical investigation, like lymphoma, esophageal cancer and prostatic carcinoma [16, 22, 23], Furthermore, it has been proved that vinorelbine is well absorbed orally with no unpredictable toxic effects and an oral formulation of the drug was registered in France in 2001 [13, 16]. The main side effect of vinorelbine is hematological toxicity. 

---